Review article


IGM Gammopathy – Differential Diagnosis, Clinical Presentation and Therapy

Dtsch Arztebl 2007; 104(26): A-1907

Hensel, M; Dreger, P; Ho, A D

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Kyle RA, Therneau TM, Rajkumar SV et al.: 3rd Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–9. MEDLINE
2. Kyle RA, Therneau TM, Rajkumar SV et al.: 3rd Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102: 3759–64. MEDLINE
3. Ropper AH, Gorson KC: Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338: 1601–7. MEDLINE
4. Waldenstrom J: Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia: A new syndrome? Acta Med Scand 1944; 117: 216–22.
5. Dimopoulos MA, Alexanian R: Waldenstrom's macroglobulinemia. Blood 1994; 83: 1452–9. MEDLINE
6. Kyle RA, Rajkumar SV, Therneau TM: 3rd Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance. Clin Lymphoma 2005; 5: 257–60. MEDLINE
7. Morel P, Monconduit M, Jacomy D: Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96: 852–8. MEDLINE
8. Garcia-Sanz R, Montoto S, Torrequebrada A: Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115: 575–82. MEDLINE
9. Dimopoulos MA, Hamilos G, Zervas K: Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 2003; 14: 1299–305. MEDLINE
10. Merlini G, Baldini L, Broglia C: Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 211–5. MEDLINE
11. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M: Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18: 214–26. MEDLINE
12. Facon T, Brouillard M, Duhamel A: Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 1: 1553–8. MEDLINE
13. Kyle RA, Treon SP, Alexanian R: Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 116–20. MEDLINE
14. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Therneau TM: Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108: 737–42. MEDLINE
15. Dimopoulos MA, Zervas C, Zomas A: Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002; 20: 2327–33. MEDLINE
16. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR: Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004; 45: 2047–55. MEDLINE
17. Treon SP, Emmanouilides C, Kimby E: Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005; 16: 132–8. MEDLINE
18. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC: Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004; 15: 1481–3. MEDLINE
19. Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999; 52: 1701–4. MEDLINE
20. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD: Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 2005; 6: 131–5. MEDLINE
21. Buske M, Dreyling M, Eimermacher H: Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic Immunocytoma (LP-IC) – results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2004; 104: 50a.
22. Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD: Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 2003; 122: 600–6. MEDLINE
23. Dreger P, Stilgenbauer S, Seyfarth B: Autologous and allogeneic stem cell transplantation (SCT) for treatment of Waldenstrom's macroglobulinemia. In: 3rd international workshop in Waldenstrom's macroglobulinemia. Paris, France, 2004, pp. 70.
24. Treon SP, Gertz MA, Dimopoulos M: Update on treatment recommendations from the 3rd international workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107: 3442–6. MEDLINE
25. Owen RG, Treon SP, Al-Katib A:Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the 2nd international workshop on Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 110 MEDLINE
e1. Niermeijer JM, Eurelings M, Lokhorst H, Franssen H, Fijnheer R, Wokke JH, Notermans NC: Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology 2006; 67: 2076–9. MEDLINE
e2. Kilidireas C, Anagnostopoulos A, Karandreas N, Mouselimi L, Dimopoulos MA: Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma 2006; 47: 859–64. MEDLINE
e3. Renaud S, Fuhr P, Gregor M, Schweikert K, Lorenz D, Daniels C, Deuschl G, Gratwohl A, Steck AJ: High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006; 66: 742–4. MEDLINE
e4. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD: Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74: 485–9. MEDLINE
e5. Weide R, Heymanns J, Koppler H: The polyneuropathy associated with Waldenstrom's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Br J Haematol 2000; 109: 838–41. MEDLINE
e6. Leblond V, Levy V, Maloisel F, Cazin B: Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 2001; 98: 2640–4. MEDLINE
e7. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R: 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 243–7. MEDLINE
e8. Tamburini J, Levy V, Chaleteix C, Fermand JP: Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia 2005; 19: 1831–4. MEDLINE
e9. Treon SP, Hunter Z, Barnagan AR: CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5: 273–7. MEDLINE
e10. Anagnostopoulos A, Hari PN, Perez WS: Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845–54. MEDLINE
e11. Tournilhac O, Leblond V, Tabrizi R: Transplantation in Waldenstrom's macroglobulinemia – the French experience. Semin Oncol 2003; 30: 291–6. MEDLINE